- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 235/10 - Radicals substituted by halogen atoms or nitro radicals
Patent holdings for IPC class C07D 235/10
Total number of patents in this class: 106
10-year publication summary
|
7
|
9
|
9
|
7
|
8
|
8
|
5
|
7
|
3
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Glaxosmithkline LLC | 528 |
5 |
| Takeda Pharmaceutical Company Limited | 2713 |
4 |
| Kumiai Chemical Industry Co., Ltd. | 313 |
4 |
| Nippon Shinyaku Co., Ltd. | 322 |
4 |
| Merial, Inc. | 211 |
3 |
| Hoffmann-La Roche Inc. | 3777 |
2 |
| Arizona Board of Regents on behalf of Arizona State University | 2924 |
2 |
| Cornell University | 3421 |
2 |
| Dana-Farber Cancer Institute, Inc. | 2657 |
2 |
| Indiana University Research and Technology Corporation | 780 |
2 |
| Jiangsu Hengrui Medicine Co., Ltd. | 694 |
2 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 710 |
2 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3001 |
2 |
| Vectus Biosystems Limited | 29 |
2 |
| Sanofi | 4294 |
2 |
| Vitae Pharmaceuticals, LLC | 41 |
2 |
| Xiamen Vivohealths Technology Co., Ltd. | 7 |
2 |
| Plex Pharmaceuticals, Inc. | 16 |
2 |
| Suzhou Mednes Pharma Tech Co., Ltd. | 3 |
2 |
| F. Hoffmann-La Roche AG | 7838 |
1 |
| Other owners | 57 |